Faron Pharmaceuticals Oy (LON:FARN) Trading Up 16.7% – Here’s What Happened

Faron Pharmaceuticals Oy (LON:FARN)’s share price shot up 16.7% on Wednesday . The company traded as high as GBX 61.50 and last traded at GBX 59.50. 97,510 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 186,179 shares. The stock had previously closed at GBX 51.

Faron Pharmaceuticals Oy Stock Performance

The stock has a market cap of £66.36 million, a price-to-earnings ratio of -2.15 and a beta of 0.36. The company has a current ratio of 1.89, a quick ratio of 1.09 and a debt-to-equity ratio of -137.93. The firm has a fifty day simple moving average of GBX 137.20 and a 200-day simple moving average of GBX 170.82.

Insider Buying and Selling

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. 4.05% of the stock is currently owned by insiders.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.